Bausch Health Companies Inc.

Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027

Bausch Health announced that its subsidiary Bausch Health Americas will redeem approximately $643 million of its 8.500% Senior Notes due 2027, funded with cash on hand. The irrevocable redemption notice is dated October 29, 2026, with the redemption date set for November 30, 2026, and the related indenture will be terminated upon completion. Retiring high-coupon debt reduces future interest expense and modestly deleverages the company, a credit-positive but non-strategic development.

•4d ago

Bausch Health Announces US$50 Million Share Repurchase Program

Bausch Health's board authorized a share repurchase program of up to US$50 million, with purchases able to begin November 3, 2026 and run no later than November 3, 2027. The stated objective is to manage potential dilution from future employee equity-based compensation, with repurchases capped at 5% of the 374,266,716 shares outstanding as of October 23, 2026. The company is not obligated to buy any particular number of shares and may suspend or discontinue the program at any time; all repurchased shares will be cancelled.

•4d ago

BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE

Bausch Health posted Q3 2026 revenue of $2.94 billion, up 10% reported and 8% organic, with GAAP EPS of $1.15 versus $0.48 a year ago and adjusted EPS of $1.77, up 53%. Adjusted EBITDA attributable to Bausch Health rose 32% to $1,305 million, and cash from operations more than doubled to $813 million; the company cut net debt by more than $500 million in the quarter. Bausch Health excluding Bausch + Lomb delivered its fourteenth consecutive quarter of YoY revenue and Adjusted EBITDA growth, with quarterly ex-B+L Adjusted EBITDA exceeding $1 billion for the first time, and management raised full-year 2026 guidance across revenue, Adjusted EBITDA, and adjusted cash flows. The board also authorized a $50 million buyback primarily to offset 2027 equity-award dilution; management remains focused on unlocking value from the Bausch Health and Bausch + Lomb assets amid the pending eye-health separation.

•4d ago

Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway

Bausch Health and its Salix Pharmaceuticals GI business announced results from a six-month, five-practice pilot study of a standardized cirrhosis clinical pathway, presented at the ACG annual meeting. Across 4,251 patients, adherence metrics improved modestly, including office visit adherence up from 46.9% to 51.1% and hepatic encephalopathy treatment rates up from 60.2% to 64.9%. The study used Cardinal Health's PPS Analytics platform and is preliminary pending peer review; it supports Salix's GI franchise positioning but carries no near-term financial impact.

•20d ago

Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets

Bausch Health and Belgian skincare innovator YUN announced the expansion of their strategic collaboration into Mexico and additional EMEA markets, with launches in the Czech Republic, Slovakia, Ukraine and Bulgaria and a Kazakhstan rollout expected in October 2026. The expansion builds on the 2025 launch in Poland, where Bausch Health added YUN's eczema-prone skincare solutions to its dermatology portfolio alongside the earlier acne-prone line based on the YUN Probiotherapy platform. No financial terms were disclosed; the announcement is incremental geographic reach for BHC's dermatology franchise rather than a new material agreement.

•1mo ago

Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia

Bausch Health and its subsidiary Solta Medical announced the availability of the next-generation Fraxel FTX skin resurfacing system in Australia beginning September 1, 2026. The Fraxel FTX platform features dual wavelengths (1927 nm and 1550 nm) and a redesigned handpiece that is 20% lighter and smaller, designed to enhance precision and patient comfort. Solta Medical will support the Australian launch with clinical education and business support for healthcare practitioners.

•2mo ago

Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board

Bausch Health CEO Thomas J. Appio has been appointed to the board of directors of its subsidiary, Bausch + Lomb, effective August 5, 2026. The parent company, which owns approximately 87% of Bausch + Lomb, also appointed three additional directors to the subsidiary's board. Four previous directors resigned to facilitate the changes, with Bausch Health noting the resignations were not due to any disagreement.

•2mo ago

BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE

Bausch Health reported second quarter 2026 revenue of $2.85 billion, a 13% increase year-over-year, with GAAP EPS of $0.68 and Adjusted EPS of $1.26, up 40% compared to the prior year. The company generated $671 million in cash from operating activities and reported cash and cash equivalents of $1.825 billion, significantly strengthening its balance sheet and reducing net debt. Based on strong performance across segments, Bausch Health raised its full-year 2026 guidance for revenue, Adjusted EBITDA, and Adjusted Cash Flows from Operations.

•3mo ago

Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China

Bausch Health's Solta Medical subsidiary announced that its flagship brand Thermage has received the AAA Well-Known Trademark Certification in China. This elite distinction is awarded by the China Trademark Association to only 217 brands nationwide, recognizing Thermage's brand reputation and market influence. The certification serves as a 'mark of trust' for consumers in China, where Thermage has over a decade of presence and has performed more than 5 million treatments worldwide.

•5mo ago